Delayed hypersensitivity with ferric carboxymaltose

Surabhi Sridhara, V. Rajesh, Ravindra Prabhu, Karan Saraf

Research output: Contribution to journalArticle

Abstract

Ferric Carboxymaltose (FCM) is widely used in the treatment of anaemia of Chronic Kidney Disease (CKD). The clinicians must be alert of the rare adverse events such as hypersensitivity with subsequent doses of Ferric carboxymaltose. Here, we report a case of a 59-year-old male a known case of CKD, with anaemia and thrombocytopenia. Ferric carboxymaltose was the treatment of choice. There was a hypersensitivity reaction to the second dose whereas, the first dose was well tolerated. This case report indicates the onset of adverse reaction with ferric carboxymaltose with the second dose even though the first dose was well tolerated.

Original languageEnglish
Pages (from-to)FD01-FD02
JournalJournal of Clinical and Diagnostic Research
Volume11
Issue number11
DOIs
Publication statusPublished - 01-11-2017

All Science Journal Classification (ASJC) codes

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Delayed hypersensitivity with ferric carboxymaltose'. Together they form a unique fingerprint.

  • Cite this